Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the first and second lines has emerged as optimal treatment strategy and has implications rel...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | RU |
| Publié: |
IP Habib O.N.
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b5ffcd19c09e4753ada4d68dd2290140 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|